VKTX Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of -- compared to Viking Therapeutics, Inc.'s net margin of 13.47%. Viking Therapeutics, Inc.'s return on equity of -46.41% beat Amgen, Inc.'s return on equity of 102.03%.

Viking Therapeutics, Inc. has a consensus price target of $92.72, signalling upside risk potential of 190.39%. On the other hand Amgen, Inc. has an analysts' consensus of $350.04 which suggests that it could fall by -7.15%. Given that Viking Therapeutics, Inc. has higher upside potential than Amgen, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Amgen, Inc..

Viking Therapeutics, Inc. has a beta of 0.756, which suggesting that the stock is 24.38% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.886%.

Viking Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.56% to investors and pays a quarterly dividend of $2.52 per share. Viking Therapeutics, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 66.92% of its earnings as a dividend. Amgen, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viking Therapeutics, Inc. quarterly revenues are --, which are smaller than Amgen, Inc. quarterly revenues of $9.9B. Viking Therapeutics, Inc.'s net income of -$157.7M is lower than Amgen, Inc.'s net income of $1.3B. Notably, Viking Therapeutics, Inc.'s price-to-earnings ratio is -- while Amgen, Inc.'s PE ratio is 26.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics, Inc. is -- versus 5.56x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Hims & Hers Health, Inc. has a net margin of -- compared to Viking Therapeutics, Inc.'s net margin of 3.34%. Viking Therapeutics, Inc.'s return on equity of -46.41% beat Hims & Hers Health, Inc.'s return on equity of 23.68%.

Viking Therapeutics, Inc. has a consensus price target of $92.72, signalling upside risk potential of 190.39%. On the other hand Hims & Hers Health, Inc. has an analysts' consensus of $22.10 which suggests that it could grow by 39.72%. Given that Viking Therapeutics, Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Hims & Hers Health, Inc..

Viking Therapeutics, Inc. has a beta of 0.756, which suggesting that the stock is 24.38% less volatile than S&P 500. In comparison Hims & Hers Health, Inc. has a beta of 2.553, suggesting its more volatile than the S&P 500 by 155.31%.

Viking Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hims & Hers Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viking Therapeutics, Inc. pays -- of its earnings as a dividend. Hims & Hers Health, Inc. pays out -- of its earnings as a dividend.

Viking Therapeutics, Inc. quarterly revenues are --, which are smaller than Hims & Hers Health, Inc. quarterly revenues of $617.8M. Viking Therapeutics, Inc.'s net income of -$157.7M is lower than Hims & Hers Health, Inc.'s net income of $20.6M. Notably, Viking Therapeutics, Inc.'s price-to-earnings ratio is -- while Hims & Hers Health, Inc.'s PE ratio is 30.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics, Inc. is -- versus 1.68x for Hims & Hers Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Viking Therapeutics, Inc.'s net margin of 34.4%. Viking Therapeutics, Inc.'s return on equity of -46.41% beat Eli Lilly & Co.'s return on equity of 104.39%.

Viking Therapeutics, Inc. has a consensus price target of $92.72, signalling upside risk potential of 190.39%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,214.34 which suggests that it could grow by 20.5%. Given that Viking Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Viking Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Viking Therapeutics, Inc. has a beta of 0.756, which suggesting that the stock is 24.38% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.355%.

Viking Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.62% to investors and pays a quarterly dividend of $1.73 per share. Viking Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viking Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Viking Therapeutics, Inc.'s net income of -$157.7M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Viking Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 44.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics, Inc. is -- versus 14.08x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Viking Therapeutics, Inc.'s net margin of -9.34%. Viking Therapeutics, Inc.'s return on equity of -46.41% beat Pfizer Inc.'s return on equity of 8.69%.

Viking Therapeutics, Inc. has a consensus price target of $92.72, signalling upside risk potential of 190.39%. On the other hand Pfizer Inc. has an analysts' consensus of $28.43 which suggests that it could grow by 6.94%. Given that Viking Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Pfizer Inc..

Viking Therapeutics, Inc. has a beta of 0.756, which suggesting that the stock is 24.38% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.474, suggesting its less volatile than the S&P 500 by 52.65%.

Viking Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.47% to investors and pays a quarterly dividend of $0.43 per share. Viking Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.85% of its earnings as a dividend.

Viking Therapeutics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Viking Therapeutics, Inc.'s net income of -$157.7M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Viking Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 19.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viking Therapeutics, Inc. is -- versus 2.42x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.